In FTC, 17–57% of tumors have RAS gene family mutations, 98% of familial MTCs have RET gene mutations, and 44% of sporadic MTCs have RET gene mutations [9]. The gene discussed is RET; the disease is thyroid cancer, nonmedullary, 2.